Edward Nash
Stock Analyst at Canaccord Genuity
(3.87)
# 597
Out of 4,667 analysts
70
Total ratings
49.15%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Buy | $37 → $44 | $38.88 | +13.18% | 8 | Nov 5, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $22 | $18.16 | +21.13% | 8 | Sep 30, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.74 | +704.60% | 6 | Aug 12, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $38 → $78 | $56.38 | +38.35% | 5 | Jul 31, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.50 | +435.12% | 3 | May 23, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $59 → $56 | $30.73 | +82.23% | 5 | May 13, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.58 | +675.19% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $2.03 | +344.44% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $322.21 | +17.01% | 8 | Mar 15, 2024 | |
| THTX Theratechnologies | Assumes: Hold | $8 | $1.21 | +561.16% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.93 | +245.18% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.97 | +270.08% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.31 | -13.42% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $2.86 | +6,187.55% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $46.75 | +75.40% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $6.10 | +1,211.48% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $5.69 | +744.33% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.87 | +10,973.25% | 1 | Nov 8, 2017 |
Verona Pharma
Nov 5, 2024
Maintains: Buy
Price Target: $37 → $44
Current: $38.88
Upside: +13.18%
Travere Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $18.16
Upside: +21.13%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.74
Upside: +704.60%
Corcept Therapeutics
Jul 31, 2024
Maintains: Buy
Price Target: $38 → $78
Current: $56.38
Upside: +38.35%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.50
Upside: +435.12%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59 → $56
Current: $30.73
Upside: +82.23%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.58
Upside: +675.19%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $2.03
Upside: +344.44%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $322.21
Upside: +17.01%
Theratechnologies
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.21
Upside: +561.16%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.93
Upside: +245.18%
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $12.97
Upside: +270.08%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.31
Upside: -13.42%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $2.86
Upside: +6,187.55%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $46.75
Upside: +75.40%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $6.10
Upside: +1,211.48%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $5.69
Upside: +744.33%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.87
Upside: +10,973.25%